Dr David Taussig completed specialist training in Haematology at St Bartholomew’s and the Royal London Hospitals.
He completed a PhD at the Cancer Research UK London Research Institute investigating characteristics of leukaemia stem cells in Dr Dominique Bonnet’s laboratory in the context of a Cancer Research UK Translational Research Fellowship from 2002–2006.
He undertook postdoctoral studies as a Senior Lecturer and Honorary Consultant at Barts Cancer Institute funded by an MRC Clinician Scientist Fellowship from 2006–2011 and then through HEFCE funding from 2011–2014.
Dr Taussig joined The Royal Marsden as a Consultant Haematologist in 2014, and became an Associate Honorary Member of Faculty at The Institute of Cancer Research in 2015.
His research has shown that acute myeloid leukaemia induces bone marrow failure by preventing normal hematopoietic stem cells from differentiating (Miraki-Moud et al PNAS 2013). Subsequently he has been studying the role of the amino acid arginine in the growth of AML. He is a member of the NCRI AML working party.
He has a laboratory in the Centre for Molecular Pathology researching the biology of acute leukaemias with a focus on acute myeloid leukaemia. He is a co-investigator on a Cancer Research UK Programme grant investigating poor risk AML with collaborators at Barts Cancer Institute, the Francis Crick Institute and Birmingham University.